Fig. (7) X-ray crystallographic complexes of a) JMJD2A with NOG, b) FBXL11 with 2-OG, c) PHF8 with NOG, d-f) JMJD2A with an oxalyltyrosine derivative, 2,4-PDCA and 5-carboxy-8-hydroxyquinoline respectively.